Recurrent seizures of autoimmune origin: emerging phenotypes.
Antibody
Auto-immune epilepsy
Encephalitis
Phenotype
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
12
09
2020
accepted:
09
02
2021
revised:
15
01
2021
pubmed:
28
2
2021
medline:
22
7
2021
entrez:
27
2
2021
Statut:
ppublish
Résumé
Recurrent seizures of autoimmune origin (AEp) are one of the most frequent causes of recurrent seizures or suspected epilepsy of unknown cause. The aim of this study was to identify specific phenotypes corresponding to AEp. We retrospectively reviewed features of patients with recurrent seizures of unknown cause and investigated for suspected AEp (January 2015-May 2018). Patients were separated in: (1) AEpAb+: AEp with positive autoantibodies; (2) AEpAb-: suspected AEp (inflammatory central nervous system (CNS) profile) without autoantibodies; (3) NAEp: epilepsy without CNS inflammation. Eighty-nine epileptic patients underwent a CSF antibody detection. From the remaining 57 epileptic patients (32 excluded for a differential diagnosis), 61.4% were considered as AEp. 21% were AEpAb+ (4 NMDAR, 2 GABAbR, 3 GAD-Ab, 2 LGi1, 1 CASPR2), 40.4% AEpAb-, and 38.6% NAE. AE (AEpAb+ and AEpAb-) was significantly associated with antibody prevalence in epilepsy (APE) score ≥ 4 (80%), encephalitic phase (71.4%), psychiatric involvement (64.7%), cognitive impairment (50%), and status epilepticus (41.2%). Within the group of 29 patients without encephalitic phase and with chronic epilepsy (NEPp), 34.5% were defined as AEp. 10.4% were AEpAb+ (2 GAD, 1 CASPR2) and 24.1% were AEpAb-. NEP AEp was associated with non-cerebral autoimmune disorders, short epileptic disease duration, and cognitive impairment. Autoimmune cause (AEp) should be assessed in patient suffering from recurrent seizures of unknown cause. Acute encephalitis is clearly the main AEp phenotype. AEp was also defined in more than one-third of chronic epilepsy patients (NEP) of unknown cause. Then, AEp may be combined with other autoimmune comorbidities, a shorter evolution of recurrent seizures, and cognitive impairment.
Identifiants
pubmed: 33638022
doi: 10.1007/s00415-021-10457-1
pii: 10.1007/s00415-021-10457-1
doi:
Substances chimiques
Autoantibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3000-3010Informations de copyright
© 2021. Springer-Verlag GmbH, DE part of Springer Nature.
Références
Hauser WA, Annegers JF, Rocca WA (1996) Descriptive epidemiology of epilepsy: contributions of population-based studies from Rochester, Minnesota. Mayo Clin Proc 71(6):576–586
pubmed: 8642887
Annegers JF, Rocca WA, Hauser WA (1996) Causes of epilepsy: contributions of the Rochester epidemiology project. Mayo Clin Proc 71(6):570–575
pubmed: 8642886
Kwan P, Brodie MJ (2000) Early identification of refractory epilepsy. N Engl J Med 342(5):314–319
pubmed: 10660394
Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M et al (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7(12):1091–1098
pubmed: 18851928
pmcid: 2607118
Navarro V, Kas A, Apartis E, Chami L, Rogemond V, Levy P et al (2016) Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis. Brain 139(Pt 4):1079–1093
pubmed: 26945884
Brenner T, Sills GJ, Hart Y, Howell S, Waters P, Brodie MJ et al (2013) Prevalence of neurologic autoantibodies in cohorts of patients with new and established epilepsy. Epilepsia 54(6):1028–1035
pubmed: 23464826
Wright S, Vincent A (2016) Progress in autoimmune epileptic encephalitis. Curr Opin Neurol 29(2):151–157
pubmed: 26886357
pmcid: 4834991
Dubey D, Alqallaf A, Hays R, Freeman M, Chen K, Ding K et al (2017) Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 74(4):397–402
pubmed: 28166327
Tecellioglu M, Kamisli O, Kamisli S, Yucel FE, Ozcan C (2018) Neurological autoantibodies in drug-resistant epilepsy of unknown cause. Ir J Med Sci 187(4):1057–1063
pubmed: 29524102
Soeder BM, Gleissner U, Urbach H, Clusmann H, Elger CE, Vincent A et al (2009) Causes, presentation and outcome of lesional adult onset mediotemporal lobe epilepsy. J Neurol Neurosurg Psychiatry 80(8):894–899
pubmed: 19357127
Gozubatik-Celik G, Ozkara C, Ulusoy C, Gunduz A, Delil S, Yeni N et al (2017) Anti-neuronal autoantibodies in both drug responsive and resistant focal seizures with unknown cause. Epilepsy Res 135:131–136
pubmed: 28675819
Gaspard N, Foreman BP, Alvarez V, Kang CC, Probasco JC, Jongeling AC et al (2015) New-onset refractory status epilepticus. Neurology 85(18):1604–1613
pubmed: 26296517
pmcid: 4642147
Süße M, Hamann L, Flöel A, von Podewils F (2019) Nonlesional late-onset epilepsy: semiology, EEG, cerebrospinal fluid, and seizure outcome characteristics. Epilepsy Behav 91:75–80
pubmed: 29941211
von Podewils F, Suesse M, Geithner J, Gaida B, Wang Z, Lange J et al (2017) Prevalence and outcome of late-onset seizures due to autoimmune etiology: a prospective observational population-based cohort study. Epilepsia 58(9):1542–1550
Vanli-Yavuz EN, Erdag E, Tuzun E, Ekizoglu E, Baysal-Kirac L, Ulusoy C et al (2016) Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis. J Neurol Neurosurg Psychiatry 87(7):684–692
pubmed: 27151964
Steriade C, Britton J, Dale RC, Godot A, Irani S, Linnoila J et al (2020) Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune associated epilepsy: conceptual definitions. Epilepsia 61:1341–1351
pubmed: 32544279
Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F et al (2016) Characterization of a subtype of autoimmune encephalitis with anti–contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 73(9):1115–1124
pubmed: 27428927
Thompson J, Bi M, Murchison AG, Makuch M, Bien CG, Chu K et al (2018) The importance of early immunotherapy in patients with faciobrachial dystonic seizures. Brain 141(2):348–356
pubmed: 29272336
Bermeo-Ovalle A (2017) Scratching the surface in autoimmune epilepsy: it is the time to dig deeper, but how? Epilepsy Curr 17(4):225–226
pubmed: 29225526
pmcid: 5716115
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15(4):391–404
pubmed: 26906964
pmcid: 5066574
Graus F, Escudero D, Oleaga L, Bruna J, Villarejo-Galende A, Ballabriga J et al (2018) Syndrome and outcome of antibody-negative limbic encephalitis. Eur J Neurol 25(8):1011–1016
pubmed: 29667271
pmcid: 6037545
Graus F, Saiz A, Lai M, Bruna J, Lopez F, Sabater L et al (2008) Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 71(12):930–936
pubmed: 18794496
pmcid: 2586945
Dubey D, Singh J, Britton JW, Pittock SJ, Flanagan EP, Lennon VA et al (2017) Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 58(7):1181–1189
pubmed: 28555833
Tekturk P, Baykan B, Erdag E, Peach S, Sezgin M, Yapici Z et al (2018) Investigation of neuronal auto-antibodies in children diagnosed with epileptic encephalopathy of unknown cause. Brain Dev 40(10):909–917
pubmed: 29935963
Modoni A, Masciullo M, Spinelli P, Marra C, Tartaglione T, Andreetta F et al (2009) Successful treatment of acute autoimmune limbic encephalitis with negative VGKC and NMDAR antibodies. Cogn Behav Neurol 22(1):63–66
pubmed: 19372772
Najjar S, Pearlman D, Zagzag D et al (2011) Spontaneously resolving seronegative autoimmune limbic encephalitis. Cogn Behav Neurol 24(2):99–105
pubmed: 21677575
Najjar S, Pearlman D, Devinsky O, Devinsky O (2013) Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review. Cogn Behav Neurol 26(1):36–49
pubmed: 23538571
Toro J, Cuellar-Giraldo D, Duque A, Minota K, Patino J, Garcia M (2017) Seronegative paraneoplastic limbic encephalitis associated with thymoma. Cogn Behav Neurol 30(3):125–128
pubmed: 28926420
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494
pubmed: 10869059
Ahmad SAB, Archer HA, Rice CM, Gerhand S, Bradley M, Wilkins A (2011) Seronegative limbic encephalitis: case report, literature review and proposed treatment algorithm. Pract Neurol 11(6):355–361
pubmed: 22100946
Fisher RE, Patel NR, Lai EC, Schulz PE (2012) Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med 37(9):e213-218.32
pubmed: 22889795
Gaspard N (2016) Autoimmune epilepsy. Continuum 22(1 Epilepsy):227–245
pubmed: 26844739
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J et al (2010) Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9(1):67–76
pubmed: 19962348
Daif A, Lukas RV, Issa NP, Javed A, VanHaerents S, Reder AT et al (2018) Antiglutamic acid decarboxylase 65 (GAD65) antibody-associated epilepsy. Epilepsy Behav 80:331–336
pubmed: 29433947
Gagnon M-M, Savard M (2016) Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature. Can J Neurol Sci 43(4):486–493
pubmed: 27030381
Falip M, Carreño M, Miró J, Saiz A, Villanueva V, Quilez A et al (2012) Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 19(6):827–833
pubmed: 22353320
Sunwoo J-S, Lee S-T, Byun J-I, Moon J, Shin J-W, Jeong D-E et al (2015) Clinical manifestations of patients with CASPR2 antibodies. J Neuroimmunol 15(281):17–22
Chen C, Wang X, Zhang C, Tao C, Shi W-X, Guan H-Z et al (2017) Seizure semiology in leucine-rich glioma-inactivated protein 1 antibody-associated limbic encephalitis. Epilepsy Behav 77:90–95
pubmed: 29050866
Ong M-S, Kohane IS, Cai T, Gorman MP, Mandl KD (2014) Population-level evidence for an autoimmune etiology of epilepsy. JAMA Neurol 1(5):569–574
Lopez-Sublet M, Bihan H, Reach G, Dupont S, Didelot A, Mourad J-j et al (2012) Limbic encephalitis and type 1 diabetes with glutamic acid decarboxylase 65 (GAD65) autoimmunity: improvement with high-dose intravenous immunoglobulin therapy. Diabetes Metab 38(3):273–275
pubmed: 22463975